Filtered By:
Management: Marketing
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 200 results found since Jan 2013.
MicroTransponder(R) Receives FDA Approval for Breakthrough Device Benefiting Stroke Survivors
The first-of-its-kind Vivistim® Paired Vagus Nerve Stimulation (VNS) System significantly improves upper limb rehabilitation therapy
DALLAS, Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- MicroTransponder, Inc. today announced United St... Devices, Neurology, FDA MicroTransponder, Vivistim Paired VNS System, Vagus Nerve Stimulation, stroke
Source: HSMN NewsFeed - August 31, 2021 Category: Pharmaceuticals Source Type: news
Infinity Neuro Receives CE Mark Approval for Their First Device to Treat Stroke
LAKE FOREST, Calif., Jan. 27, 2023 -- (Healthcare Sales & Marketing Network) --Infinity Neuro announced today that its Inspira aspiration catheters received CE Mark approval and are now commercially available in Europe. This is the first offering from Inf... Devices, Interventional, Neurology, Regulatory Infinity Neuro, Inspira aspiration catheter, stroke
Source: HSMN NewsFeed - January 27, 2023 Category: Pharmaceuticals Source Type: news
MicroTransponder Secures CMS Transitional Pass-Through Status and New Technology Add-On Payment for Its Breakthrough Stroke Rehabilitation System, Vivistim
AUSTIN, Texas, Jan. 31, 2023 -- (Healthcare Sales & Marketing Network) -- MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services (CMS) awarded the Vivistim® Paired VNS System transitional pass-through status, expand... Devices, Neurology, Reimbursement MicroTransponder, Vivistim, Stroke
Source: HSMN NewsFeed - January 31, 2023 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Can You Think Yourself Into A Different Person?
For years she had tried to be the perfect wife and mother but now, divorced, with two sons, having gone through another break-up and in despair about her future, she felt as if she’d failed at it all, and she was tired of it. On 6 June 2007 Debbie Hampton, of Greensboro, North Carolina, took an overdose of more than 90 pills – a combination of ten different prescription drugs, some of which she’d stolen from a neighbor’s bedside cabinet. That afternoon, she’d written a note on her computer: “I’ve screwed up this life so bad that there is no place here for me and nothing I can contr...
Source: Science - The Huffington Post - November 19, 2015 Category: Science Source Type: news
7 medtech stories we missed this week: Feb. 24, 2017
[Photo from unsplash.com]Several companies made distribution deals this week, while others received approval for their products. Here are 7 medtech stories we missed this week but were still worth mentioning.
1. Israel OKs E-Qure’s BST device for chronic wounds
E-Qure Corp. announced this week that it received marketing approval for its Bio-electrical Signal Therapy Device (BST Device) from the Israeli Ministry of Health, according to a Feb. 24 news release. BST is an electrotherapeutic method for treating chronic wounds. E-Qure will begin marketing its device in Israel by activating a signed distribution agreement with...
Source: Mass Device - February 24, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Electronic Medical Records Imaging Mergers & Acquisitions mHealth (Mobile Health) Regulatory/Clearance Align Technology Clarius Mobile Health Corin Group E-Qure Henry Schein Medical Nexstim Skyline Medical Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes Of Interest- An Empirical Evaluation.
Abstract
Use of disease risk score (DRS)-based confounding adjustment when estimating treatment effects on multiple outcomes is not well studied. Using an empirical example comparing dabigatran versus warfarin on ischemic stroke and major bleeding risk in 12 sequential monitoring periods (90 days each) using the Truven Marketscan database, we compared two approaches for combining DRS for multiple outcomes: (1) 1:1 matching on prognostic propensity scores (PPS), created using DRS for bleeding and stroke as independent variables in a propensity score (PS) model; and (2) simultaneous 1:1 matching on DRS for bleeding ...
Source: Am J Epidemiol - June 26, 2018 Category: Epidemiology Authors: Desai RJ, Wyss R, Jin Y, Bohn J, Toh S, Cosgrove A, Kennedy A, Kim J, Kim C, Ouellet-Hellstrom R, Karami S, Major JM, Niman A, Wang SV, Gagne JJ Tags: Am J Epidemiol Source Type: research
Learning to Walk Again
When someone suffers a stroke, he or she often loses some mobility, and some 60 percent of survivors are left with lower-limb deficits. “They usually have one leg that's more impaired than the other leg, and then they undergo rehabilitation and physical therapy. And often they don't fully recover,†said Conor Walsh, professor of engineering and applied sciences at the John A. Paulson Harvard School of Engineering and Applied Sciences and a core faculty member at the Wyss Institute for Biologically Inspired Engineering, in an interview with MD+DI.
But a new device called ReSto...
Source: MDDI - April 17, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Design Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research
